Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
Browsing: Basic > Drug Development
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new funding for chikungunya vaccine clinical…
An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.